Last Updated: Apr 07, 2016
- Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia.
Besseling Joost et al. European heart journal 2016 Apr - Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
Raal Frederick J, et al. Atherosclerosis 2016 3 - Genetic insights into statin-associated diabetes risk.
Swerdlow Daniel I, et al. Current opinion in lipidology 2016 4 (2) 125-30 - The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data.
Ramaswami Uma et al. Archives of disease in childhood 2016 Mar - The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.
Feng Q, et al. The pharmacogenomics journal 2016 2 - Statin-Associated Autoimmune Myopathy
AL Mammen. NEJM, February 18, 2016 - Seventeen years of statin pharmacogenetics: a systematic review.
Leusink Maarten et al. Pharmacogenomics 2016 Jan (2) 163-80 - Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.
Pears Robert et al. Current opinion in lipidology 2015 Jun 26(3) 162-8 - Management of Familial Hypercholesterolemia in Hong Kong.
Hu Miao et al. Journal of atherosclerosis and thrombosis 2016 Feb - Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon Ricky D et al. Canadian family physician Me´decin de famille canadien 2016 Jan 62(1) 32-7 - Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Wang Yi-Chun, et al. Medicine 2016 1 (2) e2487 - Statins for the prevention of dementia.
McGuinness Bernadette, et al. The Cochrane database of systematic reviews 2016 1 CD003160 - Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
Saavedra Yascara G Luna, et al. Journal of clinical lipidology 0 0 (6) 786-793.e1 - Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans.
Hendrie Hugh C, et al. Ethnicity & disease 2015 0 (3) 345-54 - Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada Hayato, et al. Circulation journal : official journal of the Japanese Circulation Society 2015 12 - A prognostic model based on readily available clinical data enriched a preemptive pharmacogenetic testing program.
Schildcrout Jonathan S, et al. Journal of clinical epidemiology 2015 11 - IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia.
Zhang Cai-Ping, et al. Medical hypotheses 2015 11 - CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.
Lin Jiayao, et al. Clinical laboratory 2015 0 (9) 1317-24 - Aldehyde dehydrogenase 2 (ALDH2) Glu504Lys polymorphism is associated with hypertension risk in Asians: a meta-analysis.
Jia Kui, et al. International journal of clinical and experimental medicine 2015 0 (7) 10767-72 - Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Qingtao, et al. Medicine 2015 9 (37) e1268 - Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A, et al. Die Pharmazie 2015 7 (7) 480-8 - Optimal Treatment using Statins from Childhood in Heterozygous Familial Hypercholesterolemia.
Nohara Atsushi et al. J. Atheroscler. Thromb. 2015 Sep 15. - Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East advisory panel.
Published on 2015 by Expert panel - [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document.]
Published on 2015 by Expert panel - The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Published on 2012 by Clinical Pharmacogenomics Implementation Consortium (CPIC) - Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.
Nagy Agnes, et al. BMC genetics 2015 0 (1) 108 - SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Yalena, et al. International journal of molecular sciences 2015 0 (9) 20609-19 - How Well Do Customers of Direct-to-Consumer Personal Genomic Testing Services Comprehend Genetic Test Results? Findings from the Impact of Personal Genomics Study.
Ostergren Jenny E et al. Public Health Genomics 2015 Jun 16. - Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin.
Wei Kan-Kan, et al. Clinical drug investigation 2015 9 (9) 583-91 - Angiotensin type 1 receptor A1166C gene polymorphism is associated with endothelial dysfunction and in-stent restenosis after percutaneous coronary intervention.
Li Yu, et al. International journal of clinical and experimental pathology 2015 0 (6) 7350-7
- Hot Topics (19)
- Genomics & Health Impact Scan (0)
- AMD Weekly Clips (0)
- HuGE (366)
- AMD Weekly Clips (0)
- Weekly Scan (14)
- AMD Weekly Clips (0)
- Guidelines (6)
- Evidence Classification (0)
- Weekly Scan (17)
No hay comentarios:
Publicar un comentario